The two patents cover lipid nanoparticle (LNP) manufacturing process and the chemical modification of siRNA to mitigate immune stimulation.
Tekmira Pharma said with the issuance of US patent no 7,915,399, the USPTO has granted claims covering the modification of siRNA sequences to prevent immune stimulation.
With the issuance of US patent no. 7,915,399, the USPTO has granted claims broadly covering the modification of siRNA sequences to prevent immune stimulation.
Tekmira Pharma president and CEO Mark Murray said they continue to innovate and to protect all aspects of their proprietary LNP technology, which is the gold standard in siRNA delivery.